MTM Regulatory Compliance & Ethical Standards 3 — Questions and Answers
Question 1: A pharmacist discovers during MTM that a patient is obtaining controlled substances from multiple prescribers without disclosure. What is the most appropriate initial action?
- Immediately call law enforcement to report prescription fraud
- Counsel the patient about the dangers of the practice and document the interaction (Correct answer)
- Dispense all medications without comment to maintain therapeutic alliance
- Terminate the MTM relationship and refer the patient elsewhere
Correct answer: Counsel the patient about the dangers of the practice and document the interaction
The initial ethical obligation is patient safety through counseling and documentation; mandatory reporting requirements vary by state and circumstance.
Question 2: The concept of 'therapeutic privilege'—withholding information from a patient because the pharmacist believes it would cause harm—is generally considered:
- A standard exception to informed consent widely accepted in pharmacy practice
- Ethically problematic and inconsistent with patient autonomy principles (Correct answer)
- Required when a patient has documented anxiety disorders
- Legally protected under HIPAA's psychotherapy notes exception
Correct answer: Ethically problematic and inconsistent with patient autonomy principles
Therapeutic privilege undermines patient autonomy and is broadly rejected in contemporary healthcare ethics as paternalistic.
Question 3: Which document must be provided to the patient following a Comprehensive Medication Review per CMS MTM program requirements?
- A signed consent form for MTM enrollment
- A personal medication list and medication action plan (Correct answer)
- A copy of the patient's complete pharmacy claims history
- An itemized bill of MTM services rendered
Correct answer: A personal medication list and medication action plan
CMS requires that patients receive both a personal medication list (PML) and a medication-related action plan (MAP) following a CMR.
Question 4: A pharmacy chain instructs MTM pharmacists to meet daily quotas for CMRs regardless of clinical need. This practice most directly conflicts with which ethical principle?
- Justice — because it unfairly distributes services
- Beneficence — because it prioritizes volume over patient benefit (Correct answer)
- Veracity — because it involves deception of the plan sponsor
- Autonomy — because pharmacists cannot choose their patients
Correct answer: Beneficence — because it prioritizes volume over patient benefit
Beneficence requires actions to benefit the patient; mandating CMRs to meet quotas rather than clinical need prioritizes institutional goals over patient welfare.
Question 5: Under the Americans with Disabilities Act (ADA), an MTM pharmacy must provide accommodations for patients with disabilities. Which scenario represents an ADA compliance failure?
- Offering telephone CMRs as an alternative to in-person visits
- Refusing to provide written materials in large print to a visually impaired patient who requests them (Correct answer)
- Using a qualified interpreter for a patient who communicates via sign language
- Scheduling extended appointments for patients with cognitive impairments
Correct answer: Refusing to provide written materials in large print to a visually impaired patient who requests them
Refusing to provide reasonable accommodations such as large-print materials to a person with a visual disability constitutes an ADA violation.
Question 6: Which of the following best describes the pharmacist's duty under the ethical principle of veracity during MTM?
- Sharing only positive information to maintain patient motivation
- Providing truthful, complete, and non-deceptive information to patients (Correct answer)
- Withholding negative drug interaction data if the prescriber has already decided on therapy
- Adjusting clinical findings in documentation to support the plan sponsor's quality metrics
Correct answer: Providing truthful, complete, and non-deceptive information to patients
Veracity obligates pharmacists to be truthful and transparent with patients, even when information may be unwelcome.
Question 7: A pharmacist conducting MTM is also a co-owner of a compounding pharmacy. Which regulatory/ethical issue is MOST likely present?
- Scope of practice violation under state pharmacy law
- Conflict of interest that could bias recommendations toward compounded products (Correct answer)
- Violation of CMS billing rules for duplicate MTM services
- Breach of confidentiality under HIPAA's business associate provisions
Correct answer: Conflict of interest that could bias recommendations toward compounded products
A financial interest in a compounding pharmacy creates a conflict of interest that may bias the pharmacist toward recommending compounded products unnecessarily.
MTM Regulatory Compliance & Ethical Standards 3
A pharmacist discovers during MTM that a patient is obtaining controlled substances from multiple prescribers without disclosure.
What is the most appropriate initial action?